Crescent Biopharma, Inc. Common Stock (CBIO)

Price$18.00

Value ScoreD

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)11.68%

Price vs S&P 500 (4W)-4.04%

VGM Score42.66

Market Capitalization$496.29M

All Metrics

Book Value / Share (Quarterly)$6.67

P/TBV (Annual)1.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)413.69%

Cash Flow / Share (Quarterly)$-5.67

Price vs S&P 500 (YTD)43.61%

Net Profit Margin (TTM)-990.32%

EPS (TTM)$-12.33

10-Day Avg Trading Volume0.31M

EPS Excl Extra (TTM)$-12.33

Revenue Growth (5Y)1.31%

EPS (Annual)$-14.97

ROI (Annual)-76.81%

Gross Margin (Annual)-0.50%

Net Profit Margin (5Y Avg)-86953.02%

Cash / Share (Quarterly)$6.86

ROA (Last FY)-64.90%

EBITD / Share (TTM)$-9.35

ROE (5Y Avg)-214.46%

Operating Margin (TTM)-978.04%

Cash Flow / Share (Annual)$-5.24

P/B Ratio2.70x

P/B Ratio (Quarterly)2.75x

Net Income / Employee (Annual)$-3,544,100

EV / Revenue (TTM)25.85x

ROA (TTM)-89.28%

EPS Incl Extra (Annual)$-14.97

Current Ratio (Annual)6.56x

Quick Ratio (Quarterly)13.42x

3-Month Avg Trading Volume0.25M

52-Week Price Return-10.00%

Revenue / Employee (TTM)$270,100

Tangible BV / Share (Quarterly)$0.13

P/S Ratio (Annual)45.77x

Asset Turnover (Annual)0.05x

52-Week High$27.41

Operating Margin (5Y Avg)-91877.45%

EPS Excl Extra (Annual)$-14.97

CapEx CAGR (5Y)301.37%

Tangible BV CAGR (5Y)-17.70%

26-Week Price Return19.60%

Quick Ratio (Annual)6.44x

13-Week Price Return58.87%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)13.78x

Enterprise Value$307.13M

Revenue / Share Growth (5Y)36.20%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)15.76%

Revenue / Employee (Annual)$246,500

Pretax Margin (Annual)-1401.16%

Cash / Share (Annual)$7.74

3-Month Return Std Dev102.14%

Net Income / Employee (TTM)$-3,729,000

ROE (Last FY)-76.81%

EPS Basic Excl Extra (Annual)$-14.97

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-12.33

Receivables Turnover (Annual)0.23x

ROI (TTM)-102.11%

P/S Ratio (TTM)41.77x

Pretax Margin (5Y Avg)-86945.64%

Revenue / Share (Annual)$1.04

Tangible BV / Share (Annual)$0.31

Price vs S&P 500 (52W)-34.37%

Year-to-Date Return51.77%

5-Day Price Return-8.72%

EPS Normalized (Annual)$-14.97

ROA (5Y Avg)-129.05%

Net Profit Margin (Annual)-1438.05%

Month-to-Date Return-12.83%

Cash Flow / Share (TTM)$-1.37

EBITD / Share (Annual)$-14.65

Operating Margin (Annual)-1407.52%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-214.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-12.33

P/TBV (Quarterly)4.10x

P/B Ratio (Annual)0.81x

Pretax Margin (TTM)-956.66%

Book Value / Share (Annual)$7.37

Price vs S&P 500 (13W)50.62%

Beta1.24x

P/FCF (Annual)36.31x

Revenue / Share (TTM)$0.43

ROE (TTM)-102.11%

52-Week Low$8.72

vGradeD

gGradeD

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.70est. -0.97

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.33

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CBIOCrescent Biopharma, Inc. Common Stock	D	D	B	$18.00
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Crescent Biopharma develops novel therapeutics for solid tumors, with CR-001, a bispecific antibody targeting PD-1 and VEGF designed to improve upon existing immunotherapy options. CR-001 is modeled after ivonescimab, which demonstrated superior efficacy versus Keytruda in Phase 3 testing for non-small cell lung cancer. The company is also advancing CR-002 and CR-003, antibody-drug conjugate programs targeting validated oncology indications.